These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37984034)

  • 1. Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic.
    Perry A; Wheeler-Martin K; Hasin DS; Terlizzi K; Mannes ZL; Jent V; Townsend TN; Pamplin JR; Crystal S; Martins SS; Cerdá M; Krawczyk N
    Drug Alcohol Depend; 2023 Dec; 253():111023. PubMed ID: 37984034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
    Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
    Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs.
    Austin AE; Durrance CP; Ahrens KA; Chen Q; Hammerslag L; McDuffie MJ; Talbert J; Lanier P; Donohue JM; Jarlenski M
    Drug Alcohol Depend; 2023 Jun; 247():109868. PubMed ID: 37058829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
    Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
    [No Abstract]   [Full Text] [Related]  

  • 8. Opioid-Related Trends in Active Duty Service Members During the Coronavirus Disease 2019 Pandemic.
    Sorensen IS; Susi A; Andreason P; Hisle-Gorman E; Jannace KC; Krishnamurthy J; Chokshi B; Dorr M; Wolfgang AS; Nylund CM
    Mil Med; 2023 Nov; 188(Suppl 6):567-574. PubMed ID: 37948265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
    Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
    J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
    Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
    J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disparities in receipt of medications for opioid use disorder among pregnant women.
    Henkhaus LE; Buntin MB; Henderson SC; Lai P; Patrick SW
    Subst Abus; 2022; 43(1):508-513. PubMed ID: 34270396
    [No Abstract]   [Full Text] [Related]  

  • 12. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
    Hollander MAG; Chang CH; Douaihy AB; Hulsey E; Donohue JM
    Drug Alcohol Depend; 2021 Oct; 227():108927. PubMed ID: 34358766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic.
    Nguyen T; Ziedan E; Simon K; Miles J; Crystal S; Samples H; Gupta S
    JAMA Netw Open; 2022 Jun; 5(6):e2214765. PubMed ID: 35648400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparities in opioid use disorder-related hospital use among postpartum Virginia Medicaid members.
    Martin CE; Britton E; Shadowen H; Bachireddy C; Harrell A; Zhao X; Cunningham P
    J Subst Use Addict Treat; 2023 Feb; 145():208935. PubMed ID: 36880911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
    Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
    Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.